米力农治疗慢性心衰急性加重期的临床效果及安全性探讨

Clinical Effect and Safety of Milrinone in Treatment of Acute Exacerbation of Chronic Heart Failure

目的:分析米力农治疗慢性心衰急性加重期的临床效果及安全性。方法:选取2019年6月-2020年6月在笔者所在医院接受治疗的90例慢性心衰急性加重期患者作为观察对象,用数字随机分组法将患者分为对照组和观察组,每组45例。对照组给予常规治疗,观察组接受常规治疗联合米力农治疗。比较两组治疗前后心功能、血清基质金属蛋白酶(血清MMP-9)、去甲肾上腺素(NE)及B型利尿钠肽(BNP)水平变化情况,统计两组不良反应情况及死亡率。结果:治疗前两组心功能指标及血清MMP-9、NE、BNP水平比较差异均无统计学意义(P>0.05);治疗后观察组左心射血分数(LVEF)和心脏指数(CI)均高于对照组,左室舒张末期内径(LVEDD)低于对照组,血清MMP-9、NE、BNP水平均低于对照组,差异均有统计学意义(P<0.05)。两组死亡率及不良反应发生率比较差异无统计学意义(P>0.05)。结论:米力农治疗慢性心衰急性加重期的效果好,且安全性较高,值得推广应用于临床中。

Objective:To analyze the clinical effect and safety of Milrinone in treatment of acute exacerbation of chronic heart failure.Method:A total of 90 patients with acute exacerbation of chronic heart failure treated in our hospital from June 2019 to June 2020 were selected as the observation objects,and the patients were divided into the control group and the observation group by digital randomization,with 45 patients in each group.The control group received conventional treatment,and the observation group received conventional treatment combined with Milrinone treatment.The cardiac function,serum matrix metalloproteinase(serum MMP-9),norepinephrine(NE)and B-type natriuretic peptide(BNP)changes in the two groups were compared,and the adverse reactions and mortality of the two groups were counted.Result:Before treatment,there were no significant differences in cardiac function indexes and serum MMP-9,NE and BNP levels between the two groups(P>0.05).After treatment,the left ventricular ejection fraction(LVEF)and cardiac index(CI)in the observation group were higher than those in the control group,and the left ventricular end-diastolic diameter(LVEDD)in the observation group was lower than that in the control group,serum levels of MMP-9,NE and BNP were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in mortality rate and incidence of adverse reactions between the two groups(P>0.05).Conclusion:Milrinone has considerable curative effect in the treatment of acute exacerbation of chronic heart failure,and has high safety.It is worthy of being widely used in clinical practice in the future.